Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
GT Biopharma, Inc. (GTBP) had Consolidated Net Income/Loss of $-4.52M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-4.59M |
|
-- |
|
-- |
|
$4.51M |
|
$-4.51M |
|
$-0.01M |
|
$-4.52M |
|
$-4.52M |
|
$-4.52M |
|
$-4.52M |
|
|
Consolidated Net Income/Loss |
$-4.52M |
$-4.52M |
|
$-4.51M |
|
$-4.51M |
|
1.55M |
|
1.55M |
|
$-3.00 |
|
$-3.00 |
|
| Balance Sheet Financials | |
$5.79M |
|
-- |
|
-- |
|
$5.79M |
|
$2.22M |
|
-- |
|
-- |
|
$2.22M |
|
$3.57M |
|
$3.57M |
|
$3.57M |
|
1.79M |
|
| Cash Flow Statement Financials | |
$-6.73M |
|
-- |
|
$4.88M |
|
$6.91M |
|
$5.05M |
|
$-1.85M |
|
$0.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-126.63% |
|
-126.59% |
|
-78.06% |
|
-126.59% |
|
$2.00 |
|
$-4.33 |
|
$-4.33 |
|